Track ImmuPharma PLC's receivables ($290K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
ImmuPharma PLC (IMM.L) currently reports a receivables of $290K as of June 2026. That compares with $160K in the prior-year period — up 89.3% year over year. Use the charts on this page to explore ImmuPharma PLC's receivables history and peer comparisons.
ImmuPharma PLC's receivables increased from $160K to $290K — a 89.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
ImmuPharma PLC reported $290K in receivables as of June 2026. That compares with $160K in the prior-year period — up 89.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current receivables of $290K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ImmuPharma PLC, and consider following IMM.L for alerts when major investors trade the stock.
ImmuPharma PLC is classified in the Healthcare sector. On receivables, it currently shows $290K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMM.L with unrelated industries.